PHAT Company Profile and Key Details

PHAT has shown sold momentum, gaining 20.32% over the past week and 56.38% over the past quarter, though year-to-date performance is up 115.89%. Short-term trend indicators are bearishly aligned (SMA20 16.46%, SMA50 23.2%, SMA200 85.29%). The stock’s 14-day RSI is 76.39 (overbought), while the ATR of 0.89 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 5.54% below its high and over 693.21% above its low. Average 10-day trading volume of 1.12 million shares is in line with the 3-month average of 1.03 million, indicating normal recent market interest.

Phathom Pharmaceuticals, Inc. has 70.94 million shares outstanding. The public float is 51.19 million shares, elevated short interest at 30.66% of float. This equals 13.17 million shares. The short ratio is 12.44 days. Institutional investors hold 87.67% of the float. Insiders own 4.2%. TAKEDA PHARMACEUTICAL CO LTD holds 3.76 million shares, Socks David A has 1.21 million shares and Curran Terrie has 360.46 thousand shares. Over the past six months, insider transactions show net selling. They sold 2.68 thousand shares across 3 transactions.

Phathom Pharmaceuticals, Inc. generated EPS of -$3.81 over the past year. Five-year average earnings growth is 12.5%. The latest quarter delivered EPS of -$0.41. The next quarter is forecast at -$0.42. Next year's EPS is expected at -$21.16. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $28.00 to $12.00. The high target offers 59.73% upside. The low target suggests -31.55% downside. The mean target is $25.75. This offers 46.89% upside. Phathom Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by 36.67%. The prior quarter beat by 3.95%. Over the last six quarters, Apple has recorded several small beats. These include 4.17% in August 08, 2024.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) closed at $17.60 USD, gaining $0.07 (0.39%) from the previous close of $17.53. The stock is currently within 5% of its 52-week high $2.21 and $18.28. With a market capitalization of about $1.25 billion, Phathom Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.43). Key stats such as the average daily volume over the past year has been around 1.10 million shares, in line with its 52-week average. Headquartered in Florham Park, NJ, Phathom Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven L. Basta, the company employs approximately 427 people and listed since October 25, 2019. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

Phathom Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.10. This means the shares are trading below this model’s fair value.

Phathom Pharmaceuticals, Inc. trades at a P/E ratio of -4.69, slightly below the S&P 500 average, with a price-to-sales ratio of 8.47 and a price-to-book ratio of -3.05 indicating negative book value, which may reflect financial stress. The P/FCF stands at -5.54, also below market averages.

Our AI price prediction model suggests that Phathom Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.06%, with price expected at $17.52 by January 02, 2026, within a range of $17.08 to $17.95 3-Month Outlook: Projected rise of 260.98%, reaching $63.28 by March 19, 2026, with a range of $62.30 to $67.15. 1-Year Outlook: Projected loss of -12.04%, with price at $15.42 by December 18, 2026, within a range of $14.11 to $16.78.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) shares are up 115.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Phathom Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -4.69. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $28.50, suggesting 62.58% upside. Our AI forecast model points to short-term weakness (-0.06% over two weeks), a medium-term rise (260.98% over three months), and a longer-term loss (-12.04% over one year), with expected trading ranges indicating moderate volatility.